Background
Autism spectrum disorders (ASDs) are neurodevelopmental conditions characterized by impairments or alterations in socialisation, with language changes and restricted and/or repetitive behaviours. Recent studies have estimated the prevalence of autism at 1 in 110 with evidence for a strong gender bias. Approximately four times as many males as females are diagnosed with autism based on
Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria. Children with autism commonly display abnormal development before the age of three years, particularly those with the regressive autism sub-type [
1‐
3]. Despite the distressing effects that autism can have on the lives of patients and their families, the molecular basis of this condition remains largely unknown. Consequently, there are still no effective pharmacological interventions that can ameliorate the core symptoms of autism.
A number of previous studies have attempted to elucidate pathomechanisms associated with autism using imaging, genetic and transcriptomic approaches. Although results have been sparse and sometimes conflicting across studies, a consensus has emerged which suggests changes in brain connectivity and synaptic function in autism patients [
1,
4]. Specific genes which have been implicated include
NLGN1 (neuroligin) and
NRXN1 (neurexin) [
4], and this has suggested that changes in local and distal connectivity may result from an imbalance of neuronal excitation and inhibition [
5,
6]. This may also involve dysfunction of myelination pathways, as shown by the finding of circulating antibodies against myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) in some autism patients [
7,
8].
Proteomic profiling studies have shown that brain-derived neurotrophic factor (BDNF) and glial fibrillary acidic protein (GFAP) are altered in autism patients. BDNF is a growth factor which may be related to the increased brain volumes seen in some young children with autism [
9]. This is consistent with the findings of imaging studies of autism subjects, which have identified aberrant white matter growth patterns [
10‐
12]. GFAP is an astrocytic marker and astrocytes are known to be involved in synaptic connectivity and inflammation [
13]. Increased astrocyte activity has been observed in ASD patients [
14,
15] and changes in inflammatory pathways have been observed in the cerebral cortex, white matter and cerebellum [
16]. Furthermore, circulating autoantibodies have been detected against GFAP and other proteins involved in neuronal and synaptic functions, including neurotrophic factors and neuronal-axonal filaments [
17,
18]. Finally, changes in mitochondrial and energy pathways have also been reported [
19], although it has been hypothesized that these changes may be secondary to an as yet unidentified disease process [
20]. Several independent studies have corroborated that creatine kinase (CK), an enzyme important for energy homeostasis, is one of the most robust chemical changes in autism and this is likely to parallel changes in synaptic remodelling [
21].
In order to extend these studies and increase our understanding of the proteins and biological pathways affected in autism, we have carried out a targeted proteomic profiling study of
post mortem brain samples from individuals with autism compared to controls, using selected reaction monitoring mass spectrometry (SRM-MS). SRM is an accurate, reproducible and quantitative technique to measure predetermined sets of proteins within the femto- to attomolar concentration range [
22,
23]. This method has advantages over Western blot analysis as multiple readings are taken of each analyte compared to only one for Western blot analysis [
24]. Furthermore, the targeting of peptide sequences analyzed in the SRM method makes this a highly specific and quantitative analytical method whereas the Western blot approach relies on antibody reactivity and, therefore, may result in non-specificity due to potential antibody cross reactivity [
25]. Our main objective was to identify changes in protein expression levels and to explore whether the affected proteins could be associated with the dysconnectivity hypothesis of autism.
Discussion
This is the first report presenting results from a proteomics mass spectrometry study of rare
post mortem brain tissues from autism patients and controls. Prefrontal cortex and cerebellum proteomes were investigated because a number of studies have already shown that these brain regions are affected in autism [
29‐
32]. It has previously been suggested that impaired prefrontal cortex-cerebellar circuitry may be linked to autism symptoms [
33]. In addition to its well known role in regulation of motor functions, it is now established that the cerebellum is also involved in regulation of cognition and other higher brain functions. Structural studies in non-human primates have shown that the cerebellum receives inputs through afferent nerves from several brain areas such as the prefrontal cortex which are known for their role in cognition and mood regulation [
34‐
36]. Likewise, efferent nerves from the cerebellum have been traced to both motor and non-motor areas of the frontal cortex [
37,
38], which are routed through thalamic nuclei and complete the circuit [
38]. Furthermore, functional evidence for a role of the cerebellum in higher brain function has been demonstrated by magnetic resonance imaging (MRI), which showed that activity in the cerebellar dentate nucleus correlated with changes in activity in the limbic system, parietal lobes and prefrontal cortex [
39].
The main findings of this study provide evidence that molecular processes are differentially dysregulated in different brain regions in autism, which could affect various higher functions such as cognition, working memory, mood and emotions [
40‐
42]. Here, the SRM-MS results showed decreased levels of proteins associated with myelination and increased levels of synaptic proteins in the prefrontal cortex, with opposite directional changes of the same proteins in the cerebellum. This is consistent with our unpublished observations showing decreased levels of myelin proteins in
post mortem prefrontal cortex tissue in other psychiatric disorders, such as schizophrenia, bipolar and major depressive disorder. Furthermore, dysregulation of synaptic proteins may reflect alterations in synaptic density and a comparison with published data confirms the alterations of STX1A, STXBP1 and SYN2 in autism at the mRNA level [
43]. In addition, SRM-MS showed an approximate 70% increase in the levels of CKB in the prefrontal cortex with a small non-significant decrease of this protein in the cerebellum. CKB has been used as an indicator of functional activation in magnetic resonance spectroscopy studies of the brain [
44]. Increased myelination has an important role in promoting and maintaining axon integrity by increasing axonal calibre and thereby preventing sprouting and synaptic plasticity [
45]. Moreover, decreased myelin thickness has previously been associated with disconnection of long-distance pathways, neighbouring connectivity and disruption of pathways involved in emotions [
46]. Therefore, the current findings could suggest differential regulation of local synaptic connectivity in the prefrontal cortex and the cerebellum of autism patients.
It is possible that changes in local connectivity impair the transfer of information across different brain regions, given that the higher brain functions mentioned above require co-activation of networked brain areas [
31]. Activation is known to be coordinated based on inter-regional relaying of signals through the connecting white matter tracts [
47] and previous studies in autism have found changes in connectivity and overgrowth of brain tissues [
40], along with alterations of white matter [
6,
48]. However, studies have shown that the patterns of white matter aberrations tend to differ depending on brain area, age and research techniques [
6,
40,
48]. Therefore it is interesting that the present findings identified a difference in myelination-related protein levels in the prefrontal cortex and cerebellum. As white matter is mainly comprised of glial cells and myelinated axons, the current changes in myelin-related proteins may be associated with the proposed disconnectivity in autism. Likewise, we also identified decreased levels of the immature glial cell marker VIME in both brain regions and increased levels of GFAP in the cerebellum. This may be indicative of a relative loss of astrocyte precursor cells in the cerebellum of autism patients.
Cerebellar damage can result in verbal and communication deficits, as well as a reduction of higher-order executive functions and other cognitive abilities such as language processing, visuospatial abilities and attention [
49]. Dysfunction of these pathways could be due to loss of cerebellar Purkinje cells, which has been observed in
post mortem brains from autism patients compared to controls. Interestingly, this does not appear to be related to seizure activity as patients both with and without co-morbid epilepsy showed Purkinje cell loss [
50,
51].
One limitation of the present investigation was the low statistical power for detection of proteomic changes. This resulted from the limited number of
post mortem samples available and the relatively wide age ranges of the subjects. However, the low numbers could not be avoided due to the scarcity of such high quality samples in brain banks. Moreover, the number of samples from female subjects is low due to the lower female prevalence [
52]. Also, the different age groups studied could result in a masking of some molecular changes since previous studies have shown age dependent changes in the levels of many serum proteins in children and adolescents with autism [
53]. Due to the rarity of these samples, the subjects were matched only for gender and age but not for drug treatment. Therefore, we cannot rule out the possibility that some of the changes may be medication or drug effects. Therefore, the presented findings should be considered preliminary and further validation studies should be carried out using larger sample sets, once these become available. This will require increased bio-banking efforts to allow studies involving stratification of samples by age and gender.
Acknowledgements
This work was funded by Autism Speaks Grant #6009 and the Dutch Fund for Economic Structure Reinforcement (FES) under grant agreement number 0908 (NeuroBasic PharmaPhenomics project).
All samples were obtained from the National Institute of Child Health and Human Development (NICHD) Brain and Tissue Bank for Developmental Disorders (University of Maryland School of Medicine, Baltimore, MD, USA). Approvals were granted by the Columbia University Medical School Institutional review board, consent was obtained from next of kin and all samples were de-identified and personal information anonymised. Written informed consent was obtained from the next of kin for publication of the participants’ individual details and accompanying images in this manuscript. The consent form is held by the authors’ institution/in the patients’ clinical notes and is available for review by the Editor-in-Chief. Local ethical approval for use of this tissue was granted by the Cambridgeshire Local Research Ethics Committee.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Competing interests
SB is a consultant for Myriad-RBM/Psynova Neurotech Ltd. The other authors declare no competing interests.
Authors’ contributions
JACB carried out the molecular profiling data analyses, interpreted the results, prepared the figures and tables, and wrote the manuscript. HR and PCG interpreted the results and contributing to writing and editing of the manuscript. SB conceived the study, interpreted the results and edited the manuscript. All authors read and approved the manuscript.